ard, not the relatively low bar used this year for emergency use authorization for treatments." Calling the meeting "an usual step," the AE (10/22, Neergaard, Perrone) reports Dr. Marion Gruber, director of FDA's vaccine research office, told the advisers that public scrutiny "is critical to build trust

traub, 10.31M), the Washington Times <https://www.washingtontimes.corn/news/2020/jul/27/virus-vaccine-put-to-final-test-in-thousands-of-vo/> (7/27, Neergaard, 492K), CQ Roll Call <https://www.rollcall.corn/2020/07/27/covid-19-vaccine-trial-update- novembed> (7/27, Siddons, 154K) and New York Times <https:

for treatments." Calling the meeting "an usual step," the AP <https://apnews.corn/article/virus-outbreak- e49203f5c55ba593ca587a56d0116b97> (10/22, Neergaard, Perrone) reports Dr. Marion Gruber, director of FDA's vaccine research office, told the advisers that public scrutiny "is critical to build trust a

ard, not the relatively low bar used this year for emergency use authorization for treatments." Calling the meeting "an usual step," the AP (10/22, Neergaard, Perrone) reports Dr. Marion Gruber, director of FDA's vaccine research office, told the advisers that public scrutiny "is critical to build trust

promise, mRNA technology has never been used to make a successful vaccine before." USA Today (7/27, Weintraub, 10.31M), the Washington Times (7/27, Neergaard, 492K), CQ Roll Call (7/27, Siddons, 154K) and New York Times (7/27, Grady, 18.61M), among other news outlets, also report the story. EFTA0015040

promise, mRNA technology has never been used to make a successful vaccine before." USA Today (7/27, Weintraub, 10.31M), the Washington Times (7/27, Neergaard, 492K), CQ Roll Call (7/27, Siddons, 154K) and New York Times (7/27, Grady, 18.61M), among other news outlets, also report the story. CNBC (7/27,